Journal of Clinical and Experimental Ophthalmology

Journal of Clinical and Experimental Ophthalmology
Open Access

ISSN: 2155-9570

+44 1223 790975

Milena Pahlitzsch

Milena Pahlitzsch
Charite University Medicine,
Augustenburger Platz 1, 13353 Berlin

  • Case Report
    Conjunctival Melanoma and BRAF Inhibitor Therapy
    Author(s): Milena Pahlitzsch, Eckart Bertelmann and Christian MaiMilena Pahlitzsch, Eckart Bertelmann and Christian Mai

    Background: BRAF is a proto-oncogene that encodes the protein B-Raf. This is a serine/threonine kinase and part of the mitogen-activated protein kinase (MAPK) pathway. Vemurafenib is a potent inhibitor of the mutant BRAF. It is approved for cutaneous melanoma.Patient/methods: A 80-year-old woman presented with irregular pigmented, hyperaemic upper and lower eye lid changes and alterations in the temporal conjunctiva of the right eye 03/2011. A conjunctival melanoma was detected with expression of BRAF Mutation on exon 15 (by PCR). For causal therapy the only primary surgical option was offered: exenteration of the right orbital. The patient refused this surgical intervention. To stabilize and prevent progression of the lesions, treatment with a BRAF inhibitor (vemurafenib) has been started over 16 month period of time.Results: .. View More»
    DOI: 10.4172/2155-9570.1000322

    Abstract PDF

Relevant Topics